Buda Juice Targets NYSE Listing with UltraFresh IPO

Ticker: BUDA · Form: S-1/A · Filed: Oct 20, 2025 · CIK: 2079720

Sentiment: mixed

Topics: IPO, Beverage Industry, Emerging Growth Company, Cold-Pressed Juice, NYSE Listing, Food & Beverage, S-1/A Filing

Related Tickers: BUDA

TL;DR

**BUDA's IPO is a high-risk, high-reward bet on whether 'UltraFresh' juice can truly disrupt the processed beverage market and justify its valuation.**

AI Summary

Buda Juice, LLC, soon to be Buda Juice, Inc. (BUDA), is launching its initial public offering (IPO) of 2,666,667 shares of common stock, with 2,000,000 shares offered by the company and 666,667 shares by CEO Horatio Lonsdale-Hands. The estimated IPO price range is $7.50 to $9.00 per share. The company, an 'emerging growth company,' aims to list its common stock on the NYSE under the symbol 'BUDA.' Buda Juice specializes in 'UltraFresh' cold-crafted citrus-based juices, distinguishing itself from competitors by avoiding heat treatment, HPP, and UV processing. Initially expanding through retail stores since 2014, the company strategically pivoted to selling to established retailers to scale its impact. The offering includes underwriter warrants to purchase up to 200,000 shares (or 230,000 if over-allotment is exercised) at 125% of the public offering price. Proceeds from the 666,667 shares sold by the CEO will not go to the company. The company emphasizes its SQF-certified production plant and cold-chain integrity from orchard to shelf.

Why It Matters

This IPO marks Buda Juice's transition from a Texas LLC to a Delaware corporation, aiming to capitalize on the growing demand for 'fresh' beverages. For investors, it offers an opportunity to enter the high-growth, health-conscious beverage market, but with significant risks associated with an emerging growth company and a competitive landscape dominated by established brands. Employees and customers could see benefits from increased brand visibility and potential expansion, while the broader market will observe if Buda Juice's 'UltraFresh' category can truly disrupt traditional juice processing methods and capture substantial market share against pasteurized and HPP competitors.

Risk Assessment

Risk Level: high — The filing explicitly states, 'Investing in our Common Stock involves a high degree of risk.' As an 'emerging growth company,' Buda Juice will have reduced public company reporting requirements, potentially limiting investor information. Furthermore, the company is undergoing a statutory conversion from an LLC to a corporation immediately before the IPO, which introduces structural changes and potential complexities.

Analyst Insight

Investors should carefully evaluate Buda Juice's ability to scale its 'UltraFresh' production and distribution while maintaining product integrity and competitive pricing. Given the 'high degree of risk' and the CEO selling 666,667 shares, a cautious approach is warranted, focusing on post-IPO performance and market acceptance before committing significant capital.

Financial Highlights

revenue
$11.2 million
revenue Growth
+41.8%

Revenue Breakdown

SegmentRevenueGrowth
Buda Juice (Organic)$11.2 million+41.8%
Buda Fresh (Value-Forward)$11.2 million+41.8%
Private Label Products$11.2 million+41.8%

Key Numbers

Key Players & Entities

FAQ

What is Buda Juice's core product offering?

Buda Juice specializes in 'UltraFresh' cold-crafted citrus-based juices. These products are distinguished by being 'never heat-treated, never HPP-processed and always cold,' aiming to preserve nutrients and genuine taste.

Who is the Selling Stockholder in the Buda Juice IPO?

The Selling Stockholder is Horatio Lonsdale-Hands, the Chief Executive Officer and Co-Founder of Buda Juice. He is offering 666,667 shares of common stock in the IPO, and the company will not receive any proceeds from these sales.

What is the estimated price range for Buda Juice's common stock in the IPO?

The company currently estimates that the offering price of the Common Stock sold in the Offering will be between $7.50 and $9.00 per share.

What exchange will Buda Juice's common stock be listed on?

Buda Juice has applied to list its Common Stock on the New York Stock Exchange (NYSE) under the symbol 'BUDA.' The closing of the Offering is contingent upon this successful listing.

What is the significance of Buda Juice being an 'emerging growth company'?

As an 'emerging growth company' under federal securities laws, Buda Juice has elected to comply with certain reduced public company reporting requirements for this prospectus and future filings, which may impact the level of disclosure available to investors.

What is the 'Conversion' mentioned in the Buda Juice S-1/A filing?

The 'Conversion' refers to Buda Juice, LLC's plan to undertake a statutory conversion into a Delaware corporation and change its name to Buda Juice, Inc. immediately before the effectiveness of this registration statement and the closing of the IPO.

What are the key risks associated with investing in Buda Juice?

The filing explicitly states that 'Investing in our Common Stock involves a high degree of risk.' Specific risks include those inherent to an emerging growth company, the competitive nature of the beverage market, and the uncertainties of scaling a new 'UltraFresh' product category.

How many shares is the underwriter granted an option to purchase?

The Company has granted a 45-day option to the underwriter to purchase up to an additional 300,000 shares of Common Stock sold by the Company and up to an additional 100,000 shares sold by the Selling Stockholder, solely to cover over-allotments.

What is Buda Juice's approach to food safety and quality?

Buda Juice states its SQF-certified, high-tech production plant adheres strictly to FDA safety protocols. They also maintain a cold-chain from orchard to retail shelf to preserve the integrity, freshness, and nutritional vitality of their juices.

When did Buda Juice begin its operations?

Buda Juice's journey began with its first kiosk inside a coffee shop in Plano, Texas, in 2014, after initial taste tests among family and friends.

Risk Factors

Industry Context

Buda Juice operates in the competitive beverage market, specifically the fresh juice and lemonade segment. It differentiates itself by focusing on an 'UltraFresh' cold-crafted product delivered through a continuous cold chain, avoiding traditional preservation methods like heat, HPP, or UV. This positions it between shelf-stable juices and operationally intensive in-store juicing, targeting retailers seeking to offer fresh options without the complexity.

Regulatory Implications

As an 'Emerging Growth Company,' Buda Juice benefits from certain regulatory accommodations under the JOBS Act, potentially easing disclosure burdens. However, it must comply with stringent food safety regulations (evidenced by its SQF certification) and meet the listing requirements of the NYSE. Failure to secure NYSE approval is a critical risk that would halt the IPO.

What Investors Should Do

  1. Evaluate the company's ability to maintain cold chain integrity at scale.
  2. Assess the competitive landscape and Buda Juice's differentiation strategy.
  3. Analyze the planned geographic expansion strategy and associated capital requirements.
  4. Review the terms of the IPO, including the split between company and selling stockholder shares.
  5. Monitor the NYSE listing application status.

Key Dates

Glossary

UltraFresh TM
Buda Juice's proprietary term for its cold-crafted juice products that maintain a continuous cold chain from production to retail shelf. (Key differentiator for Buda Juice, emphasizing freshness and quality without heat treatment.)
Cold Chain
A temperature-controlled supply chain that maintains a specific low-temperature range from the point of origin to the point of consumption. (Crucial to Buda Juice's product integrity, shelf life, and 'UltraFresh' claim.)
CAGR
Compound Annual Growth Rate, a measure of average annual growth over a specified period longer than one year. (Used to quantify Buda Juice's revenue growth from $5.6 million in 2022 to $11.2 million in 2024, showing a 41.8% CAGR.)
SQF-certified
Certified under the Safe Quality Food Program, a leading global food safety and quality certification program. (Indicates Buda Juice's commitment to high food safety standards in its production facility.)
Emerging Growth Company
A company with total annual gross revenues of less than $1.235 billion during its most recently completed fiscal year, eligible for certain regulatory accommodations. (Buda Juice qualifies for this status, potentially allowing for scaled disclosure requirements in its IPO.)
IPO
Initial Public Offering, the first time a company offers its stock for sale to the public. (The primary event Buda Juice is preparing for with this S-1/A filing.)
Underwriter Warrants
Options granted to the underwriters of an IPO, allowing them to purchase shares of the company's stock at a specified price. (Represents potential dilution and additional cost for the company if exercised; here, 200,000 shares at 125% of IPO price.)
Selling Stockholder
An existing shareholder (in this case, CEO Horatio Lonsdale-Hands) who is selling their shares in the IPO. (Proceeds from these sales do not benefit the company directly, impacting the net capital raised for operations.)

Year-Over-Year Comparison

This S-1/A filing represents Buda Juice's initial public disclosure for its IPO. As such, there is no prior S-1 or comparable filing to compare against. The document provides the first comprehensive look at the company's financial performance, including revenue of $11.2 million for 2024, achieving a 41.8% CAGR from 2022. It also outlines the business strategy, management team, and risk factors associated with the proposed public offering.

Filing Stats: 4,321 words · 17 min read · ~14 pages · Grade level 15 · Accepted 2025-10-17 20:12:56

Key Financial Figures

Filing Documents

USE OF PROCEEDS

USE OF PROCEEDS 32 DIVIDEND POLICY 33 CAPITALIZATION 34

DILUTION

DILUTION 35 MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION AND RESULTS OF OPERATIONS 36

BUSINESS

BUSINESS 46 MANAGEMENT 55 EXECUTIVE AND DIRECTOR COMPENSATION 62 CERTAIN RELATIONSHIPS AND RELATED PARTY TRANSACTIONS 63 PRINCIPAL AND SELLING STOCKHOLDERS 64

DESCRIPTION OF CAPITAL STOCK

DESCRIPTION OF CAPITAL STOCK 65 SHARES ELIGIBLE FOR FUTURE SALE 67 MATERIAL U.S. FEDERAL INCOME TAX CONSEQUENCES TO NON-U.S. HOLDERS OF OUR COMMON STOCK 68

UNDERWRITING

UNDERWRITING 72 LEGAL MATTERS 75 EXPERTS 75 WHERE YOU CAN FIND MORE INFORMATION 75 INDEX TO FINANCIAL STATEMENTS F-1 i Neither we nor the underwriter nor the Selling Shareholder have authorized anyone to provide any information or to make any representations other than those contained in this prospectus or in any free writing prospectus prepared by or on behalf of us or to which we have referred you. We take no responsibility for and can provide no assurance as to the reliability of any other information that others may give you. This prospectus is an offer to sell only the shares of Common Stock offered hereby, but only under circumstances and in jurisdictions where it is lawful to do so. The information contained in this prospectus or in any applicable free writing prospectus is current only as of its date, regardless of its time of delivery or any sale of our Common Stock. Our business, financial condition, results of operations and prospects may have changed since that date. For investors outside the United States: Neither we nor the underwriter have done anything that would permit this Offering or possession or distribution of this prospectus in any jurisdiction where action for that purpose is required, other than in the United States. Persons outside the United States who come into possession of this prospectus must inform themselves about, and observe any restrictions relating to, the Offering of the shares of Common Stock and the distribution of this prospectus outside the United States. This prospectus contains forward-looking statements that are subject to a number of risks and uncertainties, many of which are beyond our control. See “Risk Factors” and “Special Note Regarding Forward-Looking Statements.” ii ABOUT THIS PROSPECTUS Except where the context otherwise requires or where otherwise indicated throughout this registration statement, the terms “Buda Juice, LLC,” “Buda Juice, Inc.,&

financial statements and the related notes included elsewhere in this prospectus, before making an investment decision

financial statements and the related notes included elsewhere in this prospectus, before making an investment decision. If our listing application is not approved by the New York Stock Exchange (“NYSE”), we will not be able to consummate the Offering. Overview Buda Juice is pioneering the UltraFresh TM juice category through our end-to-end cold chain platform that delivers always cold, freshly crafted juice, lemonades and wellness shots to grocery retailers in Texas. We bridge the gap between shelf-stable products and operationally challenging in-store juicing, enabling any retailer to offer truly fresh and safe juice without infrastructure investment or operational complexity. Our breakthrough lies in solving the industry’s fundamental challenge: delivering UltraFresh TM quality on a retail scale. We maintain continuous 35°F temperature control from fruit to shelf, delivering products with 8-12 day shelf life - long enough for retail distribution yet fresh enough to preserve authentic taste. This eliminates the traditional tradeoffs between shelf life, flavor, and nutrient quality in the industry. We have validated our model through strong financial performance, growing revenue from $5.6 million in 2022 to $11.2 million in 2024, representing a 41.8% CAGR. Currently operating from our Dallas plant, we are executing a disciplined geographic expansion strategy with planned facilities in South Carolina (2026) and Arizona/Nevada (2027), enabling us to serve a large percentage of the U.S. population. Our Products Our product portfolio consists of fresh citrus juice, fresh citrus-based line of lemonades and wellness shot offerings across multiple brand lines and retail customers, all produced using our cold chain process: Products (1) Buda Juice (Organic) Wellness shots in 2 oz format Available in 2-pack and 6-pack glass bottle configurations (2) Buda Fresh – Value-Forward Offering (Non-Organic) 12 oz Lime Juice, 16 oz

View Full Filing

View this S-1/A filing on SEC EDGAR

View on Read The Filing